典型文献
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification
文献摘要：
In April 2017, the first edition Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines were released. These guidelines were based on medical evidence, as well as the accessibility and cost effectiveness of various anticancer drugs in China. The CSCO BC guidelines include regimens with a high level of evidence, good product accessibility and high consistent consensus among Chinese experts as level I recommendations. Regimens with a high level of evidence but poor product accessibility or expert consensus are included as level Ⅱ recommendations. Regimens that are clinically appli-cable but have a low evidence level are included as level Ⅲ recommendations. The CSCO BC guidelines with these hier-archical recommendations have been widely accepted and are updated once annually according to the latest research pro-gress in China and other countries.
文献关键词：
中图分类号：
作者姓名：
Jianbin Li;Zefei Jiang
作者机构：
Senior Department of Oncology,Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China
文献出处：
引用格式：
[1]Jianbin Li;Zefei Jiang-.Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification)[J].癌症生物学与医学（英文版）,2022(06):769-773
A类：
Regimens
B类：
Chinese,Society,Clinical,Oncology,Breast,Cancer,CSCO,BC,guidelines,stratification,classification,In,April,first,edition,were,released,These,medical,evidence,well,accessibility,cost,effectiveness,various,anticancer,drugs,China,regimens,high,level,good,product,consistent,consensus,among,experts,recommendations,but,poor,are,included,that,clinically,appli,cable,have,low,these,hier,archical,been,widely,accepted,updated,once,annually,according,latest,research,gress,other,countries
AB值：
0.509282
相似文献
机标中图分类号，由域田数据科技根据网络公开资料自动分析生成，仅供学习研究参考。
